The results of these trials support earlier trial data and recommendations on the use of risperidone in the specific clinical scenario of DBD symptoms in children and adolescents with comorbid ADHD and also highlight the attendant risks of weight gain and prolactin elevation. This evidence concerns the gene PRL and attention deficit-hyperactivity disorder.